Cargando…

Anti-thymocyte globulin exposure in patients with diffuse cutaneous systemic sclerosis undergoing autologous haematopoietic stem cell transplantation

INTRODUCTION: Autologous haematopoietic stem cell transplantation improves event-free survival and lung function and reduces skin thickening in patients with progressive diffuse cutaneous systemic sclerosis. Anti-thymocyte globulin is a key lymphoablative constituent of conditioning protocols and is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiu, Yu-Hsiang, Drijver, Anouk, Admiraal, Rick, van Rhenen, Anna, Nierkens, Stefan, van Laar, Jacob M, Spierings, Julia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515999/ https://www.ncbi.nlm.nih.gov/pubmed/37744043 http://dx.doi.org/10.1177/23971983231188232

Ejemplares similares

Second autologous haematopoietic stem cell transplantation in systemic sclerosis—a case report
por: van Rhijn-Brouwer, Femke C C, et al.
Publicado: (2019)

Therapeutic Drug Monitoring of Anti-Thymocyte Globulin in Allogeneic Stem Cell Transplantation: Proof of Concept
por: Meesters-Ensing, J.I., et al.
Publicado: (2022)

Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry
por: Amrani, Mohsin El, et al.
Publicado: (2020)

Information preferences about treatment options in diffuse cutaneous systemic sclerosis: A Delphi consensus study
por: Spierings, Julia, et al.
Publicado: (2021)

Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis
por: Spierings, Julia, et al.
Publicado: (2021)

Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all
por: Spierings, J., et al.
Publicado: (2021)

Anti-thymocyte globulin in haematology: Recent developments
por: Siddiqui, Salahuddin, et al.
Publicado: (2019)

The role of innate immune cells in systemic sclerosis in the context of autologous hematopoietic stem cell transplantation
por: Servaas, N. H., et al.
Publicado: (2020)

Treatment decision-making in diffuse cutaneous systemic sclerosis: a patient’s perspective
por: Spierings, Julia, et al.
Publicado: (2020)

Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin
por: Baron, Frédéric, et al.
Publicado: (2020)

Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection
por: van der Zwan, Marieke, et al.
Publicado: (2020)

B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis
por: van Laar, Jacob M
Publicado: (2010)

Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin
por: Yang, Dan, et al.
Publicado: (2019)

The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis
por: Willison, A. G., et al.
Publicado: (2022)

Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using total lymphoid irradiation and anti-thymocyte globulin conditioning
por: Rezvani, Andrew R., et al.
Publicado: (2015)

Induction of procalcitonin in liver transplant patients treated with anti-thymocyte globulin
por: Zazula, Roman, et al.
Publicado: (2007)

Rabbit anti‐thymocyte globulin for the prevention of acute rejection in kidney transplantation
por: Alloway, Rita R., et al.
Publicado: (2019)

Myeloid-derived suppressor cells are bound and inhibited by anti-thymocyte globulin
por: Suk Lee, Young, et al.
Publicado: (2019)

A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol
por: Spierings, Julia, et al.
Publicado: (2021)

Autologous Haematopoietic Stem Cell Transplantation and Systemic Sclerosis: Focus on Interstitial Lung Disease
por: Bagnato, Gianluca, et al.
Publicado: (2022)

Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis
por: Willison, A. G., et al.
Publicado: (2022)

Serotherapy as Graft-Versus-Host Disease Prophylaxis in Haematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukaemia
por: Keogh, Steven J., et al.
Publicado: (2022)

Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT
por: van der Velden, Walter J. F. M., et al.
Publicado: (2021)

Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults
por: Tjon, Jennifer M.-L., et al.
Publicado: (2021)

Anti‐thymocyte globulin‐mediated immunosenescent alterations of T cells in kidney transplant patients
por: Lee, Ga Hye, et al.
Publicado: (2022)

SENSITIZATION TO DENATURED AUTOLOGOUS GAMMA GLOBULIN
por: McCluskey, Robert T., et al.
Publicado: (1962)

Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline
por: Bayas, Antonios, et al.
Publicado: (2023)

Anti-thymocyte globulin induced non-cardiogenic pulmonary edema during renal transplantation
por: Parikh, Beena K., et al.
Publicado: (2011)

Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage
por: Malvezzi, Paolo, et al.
Publicado: (2015)

Usefulness of valacyclovir prophylaxis for cytomegalovirus infection after anti-thymocyte globulin as rejection therapy
por: Ko, Eun Jeong, et al.
Publicado: (2019)

Aplastic Anemia with Epstein-Barr Virus Reactivation after Anti-thymocyte Globulin Therapy
por: Kawarada, Yo, et al.
Publicado: (2023)

Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis
por: Simonsen, Cecilia Smith, et al.
Publicado: (2016)

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021)

Autologous haematopoietic stem cell transplantation versus low‐dose immunosuppression in secondary–progressive multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Autologous haematopoietic stem cell transplantation for neurological diseases
por: Burman, Joachim, et al.
Publicado: (2018)

Differential Elimination of Anti-Thymocyte Globulin of Fresenius and Genzyme Impacts T-Cell Reconstitution After Hematopoietic Stem Cell Transplantation
por: Oostenbrink, Lisa V. E., et al.
Publicado: (2019)

A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation
por: Mullen, John C, et al.
Publicado: (2014)

Anti-Thymocyte Globulin Induces Neoangiogenesis and Preserves Cardiac Function after Experimental Myocardial Infarction
por: Lichtenauer, Michael, et al.
Publicado: (2012)

Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies
por: Li, Qingshan, et al.
Publicado: (2015)

Serum sickness following rabbit anti-thymocyte globulin for acute vascular renal allograft rejection
por: Teng, Jessie, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_n1c1ka3o4k2u6rd7cl9pei82f4